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Abstract 22 
Background 23 
A recently-licensed 10-valent pneumococcal conjugate vaccine (PHiD-CV; Synflorix, 24 
GSK) uses Protein D from Haemophilus influenzae as a carrier protein. PHiD-CV 25 
therefore has the potential to provide additional protection against nontypeable H. 26 
influenzae (NTHi). NTHi frequently causes respiratory tract infections and is associated 27 
with significant morbidity and mortality worldwide and there is currently no vaccine.  28 
Methods 29 
We developed mouse models of NTHi infection and influenza/NTHi superinfection. Mice 30 
were immunized with PHiD-CV, heat-killed NTHi, or a 13-valent pneumococcal 31 
conjugate vaccine that did not contain Protein D (PCV13; Prevenar, Pfizer) and then 32 
infected intranasally with NTHi. 33 
Results 34 
Infection with NTHi resulted in weight loss, inflammation and airway neutrophilia. In a 35 
superinfection model, prior infection with pandemic H1N1 influenza virus (strain 36 
A/England/195/2009) augmented NTHi infection severity, even with a lower bacterial 37 
challenge dose. Immunization with PHiD-CV produced high levels of antibodies that 38 
were specific against Protein D, but not heat-killed NTHi. Immunization with PHiD-CV led 39 
to a slight reduction in bacterial load, but no change in disease outcome.  40 
Conclusions 41 
PHiD-CV induced high levels of Protein D-specific antibodies, but did not augment 42 
pulmonary clearance of NTHi. We found no evidence to suggest that PHiD-CV will offer 43 
added benefit by preventing NTHi lung infection.  44 
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Introduction 45 
Nontypeable Haemophilus influenzae (NTHi) is a common coloniser of the human 46 
nasopharynx [1], and frequently causes respiratory tract infections, including otitis media 47 
and sinusitis [2]. Occasionally, NTHi can cause serious invasive infections, including 48 
septicaemia and meningitis, particularly in individuals with underlying co-morbidities, and 49 
is associated with significant case-fatality [3, 4]. However, the main burden of disease 50 
with NTHi is pneumonia [5] and although data on the aetiology of non-bacteraemic 51 
pneumonia are limited, numerous studies have identified NTHi in lung aspirates and 52 
sputum of patients with pneumonia [6, 7]. Depending on geographical area, NTHi is 53 
either the second [8] or third [9] most common cause of community acquired pneumonia 54 
after Streptococcus pneumoniae and Mycoplasma pneumoniae. NTHi disease is most 55 
frequently associated with viral infection [10] presenting as secondary or superinfections 56 
which increase disease severity and lead to increased mortality [11]. 57 
 58 
NTHi also plays a major role in exacerbations of chronic respiratory conditions, including 59 
chronic suppurative lung disease (CSLD) and bronchiectasis in children [12, 13] and 60 
chronic obstructive pulmonary disease (COPD) in the elderly [14]. Treatments that 61 
reduce the load of bacteria, including NTHi, can improve symptoms and reduce long-62 
term lung damage [15]. However, in the absence of a licensed vaccine for NTHi [16], this 63 
is currently only possible through undesirable, prolonged multiple courses of broad-64 
spectrum antibiotics, which are associated with significant adverse effects, including the 65 
development of antibiotic resistance [17]. 66 
 67 
The recently licensed 10-valent pneumococcal conjugate vaccine (Synflorix, GSK 68 
Biologicals) (PHiD-CV) uses H. influenzae Protein D as its carrier protein for 8 of the 10 69 
pneumococcal serotypes and therefore offers a potential advantage in that it might also 70 
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prevent NTHi infections. NTHi pneumonia is the most severe manifestation of the 71 
respiratory tract infection spectrum of NTHi and much more common than invasive 72 
NTHi, therefore prevention of NTHi pneumonia should be a key goal of any NTHi 73 
vaccine. The difficulties in identifying the aetiology of non-bacteraemic pneumonia in 74 
patients mean that animal modelling is useful in determining vaccine efficacy against 75 
NTHi lung infection. If PHiD-CV was efficacious against NTHi pneumonia, it could 76 
protect millions of children and would also become an attractive alternative to the 77 
pneumococcal polysaccharide vaccine (Pneumovax 23, Merck Vaccines) (PPV23). 78 
PPV23 is routinely offered to older adults (≥65- year olds) and high-risk individuals in 79 
many countries, despite having limited protective efficacy [18]. An NTHi vaccine may 80 
also benefit older adults, who are at increased risk of NTHi infections, through 81 
establishing herd immunity, as observed following the introduction of the Haemophilus 82 
influenzae B (HiB) vaccine [19]. 83 
 84 
Protein D is a highly-conserved, surface-exposed 42 kDa outer membrane lipoprotein 85 
found in all H. influenzae strains, making it a promising vaccine candidate antigen [20]. 86 
Studies of the protective efficacy of PHiD-CV against NTHi have thus far focused on 87 
otitis media, with research into lung infections being somewhat neglected. Rats 88 
immunised with Protein D produced high titres of serum antibody against Protein D, 89 
clearing NTHi after middle ear bacterial challenge [20] and chinchillas vaccinated with 90 
Protein D showed significant protection against NTHi otitis media [21]. Passive injection 91 
of anti-Protein D antibody reduced the incidence of middle ear effusion in the chinchilla 92 
model [20]. Vaccination of human volunteers with PHiD-CV induces antibodies specific 93 
to Protein D [22, 23] and the 11-valent precursor vaccine was estimated to prevent 35% 94 
of NTHi acute otitis media episodes [24]. 95 
 96 
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The aim of the current study was to determine whether the Protein D in PHiD-CV can 97 
protect against NTHi lung infection. To test this, we developed two mouse models of 98 
NTHi lung infection (with and without prior influenza infection). We immunized mice with 99 
PHiD-CV, PCV13 (which does not contain Protein D) or heat-killed (HK) NTHi, and 100 
subsequently infected with NTHi alone or with H1N1 influenza virus followed by NTHi. 101 
We observed high levels of antibody against Protein D in mice immunized with PHiD-CV, 102 
but did not increase clearance of pulmonary NTHi.  103 
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Materials and Methods 104 
NTHi 105 
NTHi strain 162 was isolated by the Finnish Otitis Media Study Group [25] and encodes 106 
Protein D in its genome. Strain 162 is a representative of a major clade of NTHI causing 107 
otitis media, and in the Chinchilla model of infection causes purulent middle ear disease 108 
with a high density of microorganisms that persists for 3 weeks [26]. Bacteria were 109 
grown at 37°C to OD600 0.5 in brain heart infusion (BHI) broth (Difco, BD, Oxford, UK) 110 
(3.7%, w/v) supplemented with nicotinamide adenine dinucleotide (NAD; 10 μg/mL) and 111 
hemin (10 μg/mL) and washed in PBS prior to use. For enumeration, NTHi was grown 112 
on BHI agar (Difco) supplemented with 5% heat-inactivated defibrinated horse blood 113 
(Oxoid, Basingstoke, UK) in 5% CO2 at 37°C. Enumeration of NTHi from mouse samples 114 
was performed by serial dilution in 5% BHI in PBS and plating on BHI-blood agar as 115 
above. 116 
 117 
Influenza 118 
H1N1 Influenza (strain A/England/195/2009) was grown in Madin-Darby Canine Kidney 119 
(MDCK) cells, in serum free DMEM supplemented with 1 µg/mL trypsin. H1N1 Influenza 120 
strain (A/England/195/2009) was isolated by Public Health England, in the UK in April 121 
2009 [27]. The virus was harvested 3 days after inoculation and stored at -80C. Viral 122 
titre and lung viral load determined by plaque assay as previously described [28]. 123 
 124 
Mice immunizations and infection 125 
6–8 week old female BALB/c mice were obtained from Harlan UK Ltd (Speke Hall, 126 
Liverpool, UK) and kept in specific-pathogen-free conditions in accordance with the 127 
United Kingdom's Home Office guidelines and all work was approved by the Ethical 128 
Review Board at Imperial College London. Mice were immunized intramuscularly (i.m.) 129 
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with 50 μL of PHiD-CV (Lot ASPNA189CG, Synflorix, GSK, Rixart, Belgium), PCV-13 130 
(Lot F4133, Prevenar 13, Merck, UK), 10
7 
CFU of heat-killed (72°C for 1 hour) NTHi 162, 131 
or PBS. This volume is 1/10
th
 of the human dose. A boost immunization was performed 132 
at day 21. For infections, mice were anesthetized using isoflurane and infected 133 
intranasally (i.n.) with 10
7
 CFU of log phase NTHi 162 in a volume of 100 μL 5% BHI in 134 
PBS (used to maximize viability of NTHi). For superinfection experiments, mice were first 135 
infected with 5 x 10
4
 or 10
5
 PFU of influenza A H1N1 followed 7 days later by 10
5
 or 10
7
 136 
CFU of log phase NTHi 162. Mock infection was performed using 5% BHI in PBS or PBS 137 
alone. 138 
 139 
Tissue and cell recovery and isolation 140 
Mice were culled using 100 μL intraperitoneal pentobarbitone (20 mg dose, Pentoject, 141 
Animalcare Ltd. UK) and tissues collected. Blood was collected from carotid vessels and 142 
sera isolated after clotting by centrifugation. Bronchoalveolar lavage (BAL) was obtained 143 
by inflating the lungs via an intratracheal cannula with 5% BHI in PBS. Lungs were 144 
removed and homogenized by passage through 100 μm cell strainers and centrifugation 145 
at 200 x g for 5 minutes. Aliquots were removed and serially diluted for bacterial 146 
enumeration and the remainder treated with red blood cell lysis buffer (ACK; 0.15 M 147 
ammonium chloride, 1 M potassium hydrogen carbonate, and 0.01 mM EDTA, pH 7.2) 148 
before centrifugation at 200 x g for 5 minutes. The remaining cells were resuspended in 149 
RPMI 1640 medium with 10% fetal calf serum and viable cell numbers determined by 150 
trypan blue exclusion. For differential cell counts, 100 μL of cells from BAL and the lung 151 
homogenate were centrifuged onto glass slides. Samples were air dried, and fixed in 152 
methanol, before staining of with haematoxylin and eosin. 153 
 154 
Cytokine ELISA 155 
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 CXCL1/KC and IL-6 were assessed in BAL by ELISA (R&D systems) following 156 
manufacturer’s instructions. 157 
 158 
Semi-quantitative antigen specific ELISA 159 
Serum antibodies specific to Protein D or whole-cell NTHi were measured using a 160 
standardized ELISA. MaxiSorp 96-well plates (Nunc) were coated with 100 µL of 161 
formaldehyde-fixed whole-cell NTHi in PBS (50 µg/mL), or recombinant Protein D in 162 
PBS (1 µg/mL) (GSK Biologicals, Rixart, Belgium), or a combination of anti-murine 163 
lambda and kappa light chain specific antibodies (AbDSerotec, Oxford, UK) and 164 
incubated overnight at 4°C. Plates were blocked with 1% BSA in PBS. Bound IgG was 165 
detected with HRP-conjugated goat anti-mouse IgG (AbD Serotec). A dilution series of 166 
recombinant murine IgG was used as a standard to quantify specific antibodies. TMB 167 
with H2SO4 stop was used to detect the response and optical densities read at 450 nm.  168 
 169 
Statistical Analysis 170 
Comparisons of two groups were performed using Student’s t tests. Comparisons of 171 
multiple groups were performed using one- or two-way ANOVA with appropriate post-172 
tests. All statistical tests were performed using GraphPad Prism version 6.01 for 173 
Windows (GraphPad Software, San Diego California USA).  174 
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Results 175 
Characterization of NTHi infection  176 
BALB/c mice were intranasally infected with 10
7
 CFU of NTHi strain 162 in 100 μL. 177 
Weight loss was apparent after 24 hours and infected mice showed a significant 178 
reduction in weight compared to controls up to 72 hours after infection (p<0.01, Fig.1A). 179 
At two hours after infection, a bacterial load of ~5 x10
6
 CFU was recoverable from both 180 
the BAL and lungs (Fig.1B and C). After 24 hours, the concentration of viable bacteria 181 
had fallen ~100-fold in the BAL and ~50-fold in the lungs. By 48 hours, ~5 x 10
2
 CFU 182 
were remaining in both the BAL and lungs, no viable NTHi were detected by 72 hours. 183 
Airway cellular infiltration was observed after 24 hours and peaked at 48 hours (p<0.001, 184 
Fig.1D); at 72 hours, cell numbers had begun to decrease. In the lungs, cellular 185 
infiltration occurred more rapidly and persisted for longer than in BAL, with a significant 186 
increase in cell counts from 2 hours which was maintained for the entire time course of 187 
72 hours (p<0.001, Fig.1E). Differential cell counts from BAL identified a prominent 188 
airway neutrophilia, though increases in lymphocytes and macrophages were also 189 
observed (Fig.1F). In addition to the cellular markers of inflammation the pro-190 
inflammatory cytokine interleukin-6 (IL-6) (Fig.1G) and the neutrophil chemoattractant 191 
CXCL1 were detected (Fig.1H) in the BAL of infected animals. Levels of IL-6 and CXCL1 192 
in the BAL correlate well with CFU load and are rapidly reduced to levels below 193 
detection upon clearance of bacteria, with an acute peak of both mediators at 2 hours 194 
after infection and there were no detectable cytokines in the airway by 72 hours after 195 
infection. 196 
 197 
Antibody responses to immunization 198 
BALB/c mice were intramuscularly immunised with PHiD-CV, PCV13, or 10
7
 CFU of 199 
heat-killed NTHi and boosted with the same immunogen at day 21. IgG responses in 200 
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sera collected at day 35 to recombinant Protein D or whole-cell NTHi were determined 201 
by ELISA. Immunization with PHiD-CV resulted in a high titre of Protein D specific IgG 202 
(p<0.001, Fig.2A). No other immunizations induced detectable antibodies against 203 
Protein D. Sera from mice immunized with heat-killed NTHi, but no other groups, had 204 
high titres of IgG against whole-cell NTHi (p<0.05, Fig.2B). 205 
 206 
PHiD-CV does not augment pulmonary NTHi clearance 207 
BALB/c mice were intramuscularly immunised with PHiD-CV, PCV13, or 10
7
 CFU of 208 
heat-killed NTHi and boosted with the same immunogen at day 21 and infected with 10
7
 209 
CFU NTHi. To screen for augmented clearance we measured NTHi in BAL at 24 and 48 210 
hours after infection. No difference was seen between the immunized, control 211 
immunized and non-immunized groups (Fig.3A). We wished to determine whether there 212 
was an effect on disease rather than only bacterial clearance and so focussed on 48 213 
hours after infection, the peak of weight loss and cellular infiltration. 48 hours after 214 
infection, lower bacterial loads were observed for all the immunized groups compared to 215 
the non-immunized control group in the BAL (p<0.05, Fig.3B) and in the lung (p<0.001, 216 
Fig.3C), but there was no significant difference between the PHiD-CV and the PCV13 or 217 
HK-NTHi immunized groups. In the lung, both the PCV13 and HK-NTHi groups had a 218 
lower bacterial load than the non-immunized groups. However, these changes in 219 
bacterial load did not lead to a significant change in disease outcome. There was no 220 
significant difference in weight loss between the infected groups at either 24 or 48 hours 221 
after infection (Fig.3D). Cellular infiltration in the BAL was similar for all infected groups 222 
(Fig.3E), but the HK-NTHi immunized group had a significantly lower lung cell count at 223 
48 hours than the PCV13 or non-immunized groups (Fig.3F). Differential counts 224 
indicated prominent airway neutrophilia in all infected groups (Fig.3G), levels of IL-6 225 
(p<0.01, Fig.3H) and CXCL1 (p<0.01, Fig.3I) were significantly increased compared to 226 
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uninfected controls. Immunization with PHiD-CV therefore does little to augment 227 
bacterial clearance or reduce disease following infection with NTHi alone. 228 
 229 
Development of a viral-bacterial lung superinfection model 230 
Since most NTHi infections occur after viral infection, we developed a viral-bacterial 231 
superinfection model to assess the protective effect of PHiD-CV in the context of prior 232 
viral infection. Seven days after primary infection with influenza A H1N1 virus (strain 233 
A/England/195/2009), mice were infected with NTHi. Infection with either a high (10
5
 234 
PFU) or low (5 x 10
4
 PFU) dose of influenza resulted in weight loss from day 3 after 235 
infection (Fig.4A). Secondary infection with either a high (10
7
) or low (10
5
) CFU of NTHi 236 
led to further weight loss compared with influenza infection alone (p<0.05). The group 237 
that received the high dose influenza followed by the high dose NTHi was culled at 24 238 
hours after NTHi infection because the animals were approaching the humane endpoint 239 
and as such bacterial load or cell data was not collected. NTHi superinfection led to a 240 
significantly increased cellular recruitment to lungs compared to influenza infection alone 241 
(p<0.001, Fig.4B). Prior infection with influenza led to a significantly greater recovery of 242 
bacteria (p<0.05) compared to NTHi infection alone. Strikingly, influenza infection 243 
enabled NTHi infection with a 100 fold lower dose of bacteria and led to a significantly 244 
greater bacterial load than NTHi alone even when the higher dose of NTHi was used 245 
(p<0.05). Infection with 10
5
 CFU NTHi alone caused a very mild illness, compared to 246 
infection with the same bacterial inoculum after influenza infection. Mice infected with 247 
10
5 
CFU NTHi showed a 5-fold lower airway cellular infiltration and a 10-fold lower 248 
bacterial load than groups infected with influenza and NTHi (p<0.05). Whilst influenza 249 
infection alone results in inflammation, superinfection with NTHi exasperates overall 250 
disease and prior influenza infection diminishes the ability of mice to clear NTHi.  251 
 252 
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Immunization fails to protect against NTHi superinfection 253 
A superinfection protocol using 5 x 10
4
 PFU influenza and 10
5
 CFU NTHi was selected 254 
for assessment of protection by PHiD-CV. These doses were chosen as they model a 255 
typical opportunistic NTHi infection in which immunity must be compromised to establish 256 
disease, and, importantly, use a low dose for bacterial infection. No significant 257 
differences in weight change after NTHi-infection were observed between the differently 258 
immunized groups (Fig.5A). Airway bacterial loads (Fig.5B and C) and cell infiltration 259 
(Fig.5E and F) at 48 hours after NTHi infection demonstrated no evidence of protection. 260 
Airway neutrophilia was present and did not significantly differ between groups (Fig.5F), 261 
neither did IL-6 (Fig.5G) or CXCL1 (Fig.5H) levels in the BAL.  262 
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Discussion 263 
This study aimed to determine whether immunization with PHiD-CV cross-protects 264 
against NTHi lung infection. While immunization with PHiD-CV induced high levels of 265 
Protein D specific antibodies, the small reduction in bacterial load in the airways and 266 
lungs was not sufficient to affect disease outcome. Furthermore, the reduced bacterial 267 
load compared to PBS-immunized mice must be interpreted with caution, because the 268 
bacterial load in the PHiD-CV immunized mice was not significantly different to 269 
immunization with PCV13, which contains no NTHi antigens. PHiD-CV immunization did 270 
not protect against disease or reduce bacterial load in the influenza A-NTHi 271 
superinfection model. One limitation is that we only tested one dose regime of the 272 
vaccine (1/10
th
 human dose), other doses may have had different efficacy, though the 273 
dose used is a larger bolus of vaccine per muscle mass than used in humans. Only one 274 
strain of NTHi was tested in this study, 162, and it may be that PHiD-CV is protective 275 
against other strains, The significant strain heterogeneity is exactly the rationale for 276 
assessing PD as a vaccine candidate, as it is highly conserved across NTHi. Therefore, 277 
if an effect was observed it would be theoretically be expected for the majority of NTHi 278 
strains. NTHi strain 162 is an upper respiratory tract pathogen isolated from a child in 279 
Finland [25], it was chosen on account of good growth in media and virulence in mice 280 
upon i.n. infection into the lung in our preliminary studies and virulence in other models 281 
[26]. Based on the immunisation and challenge regime used in this study we conclude 282 
that PHiD-CV immunisation does not reduce bacterial load or disease after NTHi lung 283 
infection or superinfection.  284 
 285 
Protection against lung infection by PHiD-CV has not been previously investigated. 286 
Previous research has focused on the protective efficacy of Protein D against NTHi-287 
induced otitis media. Whilst enhanced pulmonary clearance of NTHi has been reported 288 
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with other NTHi immunogens in mice [29], these studies assessed bacterial load at very 289 
acute time points after infection (≤6 hours) compared to the 24 and 48 hour timepoints in 290 
our study. Longer timepoints have the advantage of allowing assessment of disease 291 
itself. As observed in our study, reduced bacterial load had no impact on disease 292 
outcome in previous studies [29, 30]. 293 
 294 
The minimal protection observed against disease in our study reflects the recent clinical 295 
trial experience. Although prevention of 35% of NTHi acute otitis media episodes was 296 
observed after immunisation with the 11-valent precursor vaccine [24], a recent study 297 
observed only a trend towards reduction but no significant effect on NTHi otitis media 298 
[31]. Other studies have reported an inconsistent effect on NTHi carriage, despite the 299 
induction of high levels of Protein D antibodies [32-34]. Lack of an effect on NTHi 300 
carriage is significant as nasopharyngeal colonization is considered a prerequisite to 301 
lung infection [35, 36]. The protective role of Protein D antibodies has also been called 302 
into question by recent studies reporting that children with a history of recurrent acute 303 
otitis media have significantly higher serum IgG concentrations against several NTHi 304 
proteins, including Protein D, compared with healthy controls [37]. 305 
 306 
Why do antibodies against Protein D not protect against disease, in spite of bactericidal 307 
activity against NTHi? Firstly, published bactericidal activity was demonstrated in vitro 308 
using serum which may not be representative of antibody and complement profiles in the 309 
airway [38]. Secondly, antibody raised against the Protein D present in PHiD-CV may 310 
not be active against the whole organism [38]. In our assays, antibodies against Protein 311 
D did not bind whole-cell NTHi. This lack of efficacy against the whole organism may be 312 
due to differences in structure between the vaccine Protein D (a delipidated recombinant 313 
protein) and naturally expressed Protein D, which occurs in NTHi as a lipoprotein [39]. 314 
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Alternatively, antibodies raised by Protein D in PHiD-CV may not be specific for surface-315 
exposed Protein D epitopes on whole NTHi. Though Protein D is a surface exposed 316 
protein, it is highly conserved among H. influenzae suggesting that it is under little 317 
immune pressure [40]. The lack of protection observed may be influenced by the 318 
challenge dose used, which though similar to other studies [41, 42], may overwhelm 319 
local antibody responses, particularly as pneumonia is probably caused by micro-320 
aspiration of the nasopharyngeal microflora seeding the lung with a relatively small 321 
amount of bacteria. However, no protection was observed in our superinfection model 322 
which used a two-log lower challenge dose. Furthermore, the infection dose was similar 323 
to the reported concentration of NTHi in the nasopharynx of children [34]. It was 324 
surprising that the heat killed NTHi failed to protect against subsequent lung infection 325 
and this may reflect limitations of the mouse model for lung bacterial infections. The 326 
route of immunisation may also have had an impact on the protection; intramuscular 327 
immunization, although it generates high levels of antibodies in serum, may not induce 328 
sufficiently strong local mucosal responses. As NTHi is a mucosal pathogen, mucosal 329 
immunization might be a more effective route for protection [43]. Finally, as observed 330 
with other bacterial lung infection models in mice [42, 44], the bacteria were cleared 331 
rapidly from the lungs indicating a strong and rapid protective innate response, which 332 
may mask any adaptive immune contribution.  333 
 334 
Irrespective of the presence or absence of Protein D antibodies, we observed rapid 335 
clearance of NTHi from the airways of mice within 72 hours, associated with a prominent 336 
neutrophilia. This is consistent with previous literature showing the importance of 337 
neutrophils in the clearance of NTHi from the lungs of mice [45]. Innate recognition of 338 
NTHi-derived lipooligosaccharide by TLR4 on alveolar macrophages and epithelial cells 339 
leads to rapid production of pro-inflammatory cytokines sufficient for clearance of NTHi 340 
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from the mouse respiratory tract [46]. There was no difference in disease severity 341 
between immunized and non-immunized mice and only a limited difference in clearance 342 
of NTHi, suggesting that the innate inflammatory response was the major factor in 343 
eliminating NTHi. Greater inflammation was associated with accelerated bacterial 344 
clearance in a model of cigarette smoke exposure and bacterial challenge [47] and 345 
COPD patients have an impaired innate response, which may contribute to their 346 
susceptibility to bacterial lung infection [48] supporting the importance of the innate 347 
response in controlling NTHi. 348 
 349 
The precise mechanisms by which colonisation leads to disease are not well-350 
understood, but intercurrent or prior viral infection has been postulated to promote local 351 
invasion [2]. Previous studies have demonstrated that prior infection with either 352 
rhinovirus (RV) [49], or respiratory syncytial virus (RSV) [50], increases NTHi bacterial 353 
load in the lungs and upper airways. Here, we show for the first time that infection with 354 
influenza increases bacterial load and disease severity following NTHi infection. Severe 355 
viral infection is hypothesized to dampen the innate response and facilitate bacterial 356 
infection and we observed impaired NTHi clearance after viral infection. If the innate 357 
response is a major requirement for clearing NTHi lung infection, then the induction of a 358 
strong antibody response would likely have little additional protective effect. It is possible 359 
that antibody-dependent bacterial killing may be more important for preventing invasive 360 
disease, while prevention of pneumonia predominantly involves antibody-independent 361 
mechanisms. 362 
 363 
Overall, the results indicate that PHiD-CV provides minimal protection against NTHi 364 
infection in an experimental mouse model, despite induction of high levels of antibodies 365 
against Protein D. There are limits translating these findings from the mouse model to 366 
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humans, but, in combination with the lack of a clear protective effect against carriage in 367 
recent clinical trials, we believe that PHiD-CV is unlikely to offer any additional benefit 368 
against NTHi pneumonia.  369 
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Figure Legends 544 
Figure 1. Timecourse of NTHi lung infection. Mice were infected i.n. with 100µL 545 
volume of 10
7
 CFU NTHi (filled circles) or mock-infected with 5% BHI in PBS (open 546 
circles) and weights measured at indicated timepoints (A). CFU/mL counts were 547 
determined from BAL (B) and the lungs (C). Cellular infiltration was measured in BAL (D) 548 
and the lungs (E). Differential counts identified numbers of lymphocytes (filled squares), 549 
macrophages (filled diamonds), and neutrophils (filled triangles) in BAL. IL-6 (G) and 550 
CXCL1 (H) in BAL measured by ELISA. Points represent individual mice. Lines 551 
represent mean values. ** p<0.01, *** p<0.001, calculated using two-way ANOVA and 552 
Sidak’s test (A), or one-way ANOVA and Tukey’s test (B-E). This was a single 553 
experiment. 554 
 555 
Figure 2. Serum antibody titres after immunization. Mice were immunized i.m. with a 556 
50 µL volume of PHiD-CV (filled circles), PCV-13 (filled triangles), 10
7
 CFU of heat-killed 557 
NTHi (filled squares), or PBS (inverted open triangles) and boosted at day 21. IgG titres 558 
against recombinant Protein D (A) or whole-cell NTHi (B) were determined at day 35. 559 
Points represent individual mice. Lines represent mean values. * p<0.05, *** p<0.001, 560 
calculated using one-way ANOVA and Tukey’s test. This is pooled data from 2 561 
experiments. 562 
 563 
Figure 3. Effect of immunization on NTHi infection of lungs. 564 
Mice were immunized i.m. with a 50 µL volume of PHiD-CV (filled circles), PCV-13 (filled 565 
triangles), 10
7
 CFU of heat-killed NTHi (filled squares), or PBS (inverted open triangles) 566 
and boosted at day 21 and infected i.n. with 10
7 
CFU NTHi on day 35. Uninfected 567 
controls received mock-immunization with PBS and mock-infection with 5% BHI in PBS 568 
(open circles). CFU/mL counts in BAL (A) were measured 24 and 48 hours after 569 
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infection. Mice were immunised under the same regime and CFU/mL counts in BAL (B) 570 
and the lungs (C) measured 48 hours after infection. Weight change was monitored (D) 571 
and cellular infiltration in BAL (E) and lungs (F) and neutrophil influx in BAL (G), IL-6 (H) 572 
and CXCL1 (I) in BAL measured by ELISA at 48 hours after infection. Points represent 573 
individual mice. Lines represent mean values. * p<0.05, ** p<0.01, *** p<0.001, 574 
calculated using one-way ANOVA and Tukey’s test. Panel A is a separate repeat to the 575 
data presented in the other panels. This figure shows the data from 2 studies. 576 
 577 
Figure 4. Influenza-NTHi superinfection model. Mice were infected i.n. with 100µL 578 
volume of 10
5
 (red icons) or 5 x 10
4
 PFU of Eng/195 H1N1 influenza (blue icons) or 579 
mock infected with PBS (black icons), 7 days later mice were infected with 10
7
 (circles) 580 
or 10
5
 CFU of NTHi (inverted triangles) or mock-infected with 5% BHI in PBS (open 581 
circles) and weights measured at indicated timepoints (A). Cellular infiltration (B) and 582 
CFU/mL counts (C) were determined from BAL 48 hours after infection with NTHi. Points 583 
represent individual mice. Lines represent mean values. In panel A ** represents p<0.01 584 
between Low flu/High NTHi and Low Flu/No NTHi and # represents p<0.05 between 585 
Low flu/Low NTHi and Low Flu/No NTHi. In panels B, C, * p<0.05, *** p<0.001, 586 
calculated using one-way ANOVA and Tukey’s test. This was a single experiment. 587 
 588 
Figure 5. Effect of immunization on Influenza-NTHi superinfection. Mice were 589 
immunized i.m. with a 50 µL volume of PHiD-CV (filled circles), PCV-13 (filled triangles), 590 
10
7
 CFU of heat-killed NTHi (filled squares), or PBS (inverted open triangles) and 591 
boosted at day 21 and infected i.n. with 5 x 10
4 
PFU of H1N1 influenza at day 35. 7 days 592 
after influenza infection, mice were infected i.n. with 10
7
 CFU/mL NTHi. Flu-infected only 593 
controls were mock-infected with 5% BHI in PBS at the NTHi infection step (open 594 
circles). Weight change was monitored (A). CFU/mL counts in BAL (B) and lungs (C), 595 
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cellular infiltration in BAL (D) and lungs (E) neutrophil influx in BAL (F) and IL-6 (G) and 596 
CXCL1 (H) in BAL were measured 48 hours after infection with NTHi. Points represent 597 
individual mice. Lines represent mean values. * p<0.05 calculated using one-way 598 
ANOVA and Tukey’s test. This was a single experiment. 599 
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